Dawn of a Post-Venture Era:

The New Face of Innovation & Translational Research

Mark Edwards Mark Edwards
Venture capital has become increasingly risk adverse. What are the new models for funding translational research in an academic environment?
View Attached Document

Bold new approaches are needed to propel biomedical discoveries from benchtop to bedside. Research institutions are forming strategic collaborations, unlocking new sources of capital and adopting new research models to accelerate the translation of basic research to new medicines that address unmet medical needs. This BIO presentation explores novel approaches taken by leading institutions to transform research breakthroughs into outstanding patient care. From self-financing of start-up companies, to commercialization alliances with top pharmaceutical companies, to public/private partnerships, a new gold standard is emerging for how academic, industry and government partners can fund innovation.